Show simple item record

dc.contributor.authorMeyers, Barnett S.
dc.contributor.authorFlint, Alastair J.
dc.contributor.authorRothschild, Anthony J.
dc.contributor.authorMulsant, Benoit H.
dc.contributor.authorWhyte, Ellen M.
dc.contributor.authorPeasley-Miklus, Catherine
dc.contributor.authorPapademetriou, Eros
dc.contributor.authorLeon, Andrew C.
dc.contributor.authorHeo, Moonseong
dc.contributor.authorAppelbaum, Paul S.
dc.contributor.authorCandilis, Philip J.
dc.contributor.authorByatt, Nancy
dc.contributor.authorDeligiannidis, Kristina M.
dc.date2022-08-11T08:10:28.000
dc.date.accessioned2022-08-23T17:10:20Z
dc.date.available2022-08-23T17:10:20Z
dc.date.issued2009-08-01
dc.date.submitted2012-11-07
dc.identifier.citationArch Gen Psychiatry. 2009 Aug;66(8):838-47. <a href="http://dx.doi.org/10.1001/archgenpsychiatry.2009.79" target="_blank">Link to article on publisher's site</a> Additional collaborators and STOP-PD Group Members from the University of Massachusetts Medical School: P. Appelbaum, MD; P. J. Candilis, MD; D. Guerin, MS; C. Wood, MS; A. Rohrbaugh, MS; S. Fratoni; C. Calkins; J. Grogan; M. Martin; J. Patel, MD; E. Smith, MD; R. Reni, MD; D. Sit, MD; E. Kayatekin, MD; D. Morin, MD; C. Cimpeanu, MD; T. Shteinlukht, MD; M. Vemuri, MD; M. Bell, MD; P. Burke, MD; N. Byatt, MD; R. Cook, MD; K. Deligiannidis, MD; I. Guryanova, MD; A. Jastiniah, MD; and A. Mathur, MD.
dc.identifier.issn0003-990X (Linking)
dc.identifier.doi10.1001/archgenpsychiatry.2009.79
dc.identifier.pmid19652123
dc.identifier.urihttp://hdl.handle.net/20.500.14038/46025
dc.description.abstractCONTEXT: Evidence for the efficacy of combination pharmacotherapy has been limited and without positive trials in geriatric patients with major depression (MD) with psychotic features. OBJECTIVES: To compare remission rates of MD with psychotic features in those treated with a combination of atypical antipsychotic medication plus a serotonin reuptake inhibitor with those treated with antipsychotic monotherapy; and to compare response by age. DESIGN: Twelve-week, double-blind, randomized, controlled trial. SETTING: Clinical services of 4 academic sites. Patients Two hundred fifty-nine subjects with MD with psychotic features randomized by age ( or =60 years) (mean [standard deviation (SD)], 41.3 [10.8] years in 117 younger adults vs 71.7 [7.8] years in 142 geriatric participants). Intervention Target doses of 15 to 20 mg of olanzapine per day plus masked sertraline or placebo at 150 to 200 mg per day. Main Outcome Measure Remission rates of MD with psychotic features. RESULTS: Treatment with olanzapine/sertraline was associated with higher remission rates during the trial than olanzapine/placebo (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.12-1.47; P < .001); 41.9% of subjects who underwent combination therapy were in remission at their last assessment compared with 23.9% of subjects treated with monotherapy (chi(2)(1) = 9.53, P = .002). Combination therapy was comparably superior in both younger (OR, 1.25; 95% CI, 1.05-1.50; P = .02) and older (OR, 1.34; 95% CI, 1.09-1.66; P = .01) adults. Overall, tolerability was comparable across age groups. Both age groups had significant increases in cholesterol and triglyceride concentrations, but statistically significant increases in glucose occurred only in younger adults. Younger adults gained significantly more weight than older subjects (mean [SD], 6.5 [6.6] kg vs 3.3 [4.9] kg, P = .001). CONCLUSIONS: Combination pharmacotherapy is efficacious for the treatment of MD with psychotic features. Future research must determine the benefits vs risks of continuing atypical antipsychotic medications beyond 12 weeks. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00056472.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19652123&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840400/pdf/nihms-178861.pdf
dc.subjectAntipsychotic Agents
dc.subjectBenzodiazepines
dc.subjectDepressive Disorder, Major
dc.subjectDouble-Blind Method
dc.subjectDrug Therapy, Combination
dc.subjectHumans
dc.subjectPlacebos
dc.subjectPsychotic Disorders
dc.subjectSerotonin Uptake Inhibitors
dc.subjectSertraline
dc.subjectTreatment Outcome
dc.subjectPsychiatry
dc.titleA double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD)
dc.typeJournal Article
dc.source.journaltitleArchives of general psychiatry
dc.source.volume66
dc.source.issue8
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/psych_pp/551
dc.identifier.contextkey3452337
html.description.abstract<p>CONTEXT: Evidence for the efficacy of combination pharmacotherapy has been limited and without positive trials in geriatric patients with major depression (MD) with psychotic features.</p> <p>OBJECTIVES: To compare remission rates of MD with psychotic features in those treated with a combination of atypical antipsychotic medication plus a serotonin reuptake inhibitor with those treated with antipsychotic monotherapy; and to compare response by age.</p> <p>DESIGN: Twelve-week, double-blind, randomized, controlled trial.</p> <p>SETTING: Clinical services of 4 academic sites. Patients Two hundred fifty-nine subjects with MD with psychotic features randomized by age ( or =60 years) (mean [standard deviation (SD)], 41.3 [10.8] years in 117 younger adults vs 71.7 [7.8] years in 142 geriatric participants). Intervention Target doses of 15 to 20 mg of olanzapine per day plus masked sertraline or placebo at 150 to 200 mg per day. Main Outcome Measure Remission rates of MD with psychotic features.</p> <p>RESULTS: Treatment with olanzapine/sertraline was associated with higher remission rates during the trial than olanzapine/placebo (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.12-1.47; P < .001); 41.9% of subjects who underwent combination therapy were in remission at their last assessment compared with 23.9% of subjects treated with monotherapy (chi(2)(1) = 9.53, P = .002). Combination therapy was comparably superior in both younger (OR, 1.25; 95% CI, 1.05-1.50; P = .02) and older (OR, 1.34; 95% CI, 1.09-1.66; P = .01) adults. Overall, tolerability was comparable across age groups. Both age groups had significant increases in cholesterol and triglyceride concentrations, but statistically significant increases in glucose occurred only in younger adults. Younger adults gained significantly more weight than older subjects (mean [SD], 6.5 [6.6] kg vs 3.3 [4.9] kg, P = .001).</p> <p>CONCLUSIONS: Combination pharmacotherapy is efficacious for the treatment of MD with psychotic features. Future research must determine the benefits vs risks of continuing atypical antipsychotic medications beyond 12 weeks.</p> <p>TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00056472.</p>
dc.identifier.submissionpathpsych_pp/551
dc.contributor.departmentDepartment of Psychiatry
dc.source.pages838-47


This item appears in the following Collection(s)

Show simple item record